Brief: Glenmark Specialty SA Receives U.S. FDA Approval For Fluticasone Propionate Inhalation Aerosol Usp, 44 Mcg Per Actuation, With 180-Day Competitive Generic Therapy Exclusivity
04/03/2026 12:02
March 4 (Reuters) - Glenmark Pharmaceuticals Ltd GLEN.NS: GLENMARK SPECIALTY SA RECEIVES U.S. FDA APPROVAL FOR FLUTICASONE PROPIONATE INHALATION AEROSOL USP, 44 MCG PER ACTUATION, WITH 180-DAY COMPETITIVE GENERIC THERAPY EXCLUSIVITY GLENMARK PHARMA - TO DISTRIBUTE FLUTICASONE PROPIONATE INHALATION AEROSOL IN U.S. STARTING MARCH 2026 Source text: ID:nPn2YYB0ka Further company coverage: GLEN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Glenmark Pharmaceuticals
See all newsBrief: Glenmark Pharma Says Unit Launches Ryaltris Nasal Spray In Brazil For Allergic Rhinitis
Brief: Glenmark Pharma US Unit Launches Calcium Gluconate Injection USP In Multiple Vial Sizes
India's Glenmark Pharma gains most in three weeks on US approval for Flonase nasal spray
Brief: Glenmark Pharma Gets U.S. FDA Approval For Fluticasone Propionate Nasal Spray 0.05 Mg/Spray
India's Glenmark Pharmaceuticals falls as brokerage flags softer-than-expected quarter